Reports
Sale
Europe Biosimulation Market Size, Share, Growth, Report: By Product Type: Software, Services; By Application: Drug Development, Drug Discovery, Other Applications; By Delivery Type: Subscription Model, Ownership Model; By End User: Biotechnology & Pharmaceutical Companies, Others; Regional Analysis; Supplier Landscape; 2024-2032
Europe Biosimulation Market Outlook
The global biosimulation market size was valued at USD 3.5 billion in 2023, with Europe holding a significant market share. The market is driven by technological advancements in biosimulation platforms and tools. It is expected to grow at a CAGR of 16.90% during the forecast period of 2024-2032, with the values likely to attain USD 14.1 billion by 2032.
Key Takeaways
- Recent data suggests that 25% of all annual cancer cases occur in Europe, with nearly half of the population at risk of developing cancer at some point in their lives . The rising emphasis on accelerating oncology drug development, fuelled by the growing number of cancer cases, is expected to surge market demand.
- One of the major Europe biosimulation market trends is the increased collaborative initiatives among the key market players to utilize biosimulation platforms in clinical applications. In March 2024, Exploristics and Exonate Ltd announced a successful collaboration involving the optimisation of clinical trial designs for Exonate’s upcoming Phase IIb study by leveraging Exploristics’ KerusCloud (a simulation-guided study design platform).
- In March 2023, Certara, Inc., announced the launch of Simcyp™ PBPK Simulator Version 22, adding novel and updating existing features of its population-based modeling and simulation platform. The launch of such technologically advanced biosimulation systems is likely to elevate market value.
Europe Biosimulation Market Analysis
Biosimulation is a comparatively newer tool in pharmaceutical drug development that enables researchers to simulate complex biological systems. Several leading market players are actively integrating biosimulation software in their drug development pipelines, owing to its ability to predict drug behavior, optimize treatment strategies, and reduce costs and time compared to conventional experiments. Thus, the rising adoption of biosimulation platforms by pharmaceutical and biotechnology companies is significantly contributing to the Europe biosimulation market growth.
Biosimulation can prove helpful in predicting the long-term outcomes of therapies for chronic diseases including cancer. In Europe, with rising prevalence of cancer, predictive models are increasingly utilized to develop effective treatments. Recent data suggests that 25% of all annual cancer cases occur in the region, with nearly half of the population in Europe at risk of developing cancer at some point in their lives (the cumulative risk estimated to be 49.3%). The rising emphasis on accelerating oncology drug development, fuelled by the growing number of cancer cases in the region, is expected to surge the Europe biosimulation market demand.
Increased collaborative initiatives among the prominent market players facilitate the sharing of resources and expertise, enabling the translation of biosimulation research into clinical applications. In March 2024, Exploristics (a United Kingdom-based provider of bio-simulation software and biostatistics services) and Exonate Ltd (a pharmaceutical company in England) announced a successful collaboration involving optimizing the clinical trial design for Exonate’s upcoming Phase IIb study by leveraging Exploristics’ KerusCloud (a simulation-guided study design platform). The companies were able to establish an enhanced study design for Exonate’s lead candidate, EXN407, an investigational topical treatment for retinal vascular diseases, by using KerusCloud. The increased application of such simulation platforms to reduce risks, cost, and duration associated with a clinical study is likely to boost the Europe biosimulation market share in the forecast period.
Technological advancements in biosimulation software enable more accurate predictions of complex biological processes, such as drug metabolism and pharmacodynamics. Continuous improvement and innovation in the existing biosimulation models is poised to fuel market growth. In March 2023, Certara, Inc., a global leader in drug discovery and development through biosimulation technology, announced the launch of Simcyp™ PBPK Simulator Version 22, adding novel and updating existing features of its population-based modeling and simulation platform. The new pharmacokinetics (PBPK) platform has expanded capabilities for a diverse range of populations and therapeutics types, thereby advancing the drug development process. The release of such innovative biosimulation platforms supported by substantial investments from pharmaceutical companies is anticipated to elevate the market value in coming years.
Europe Biosimulation Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Product Type | Services, Software |
| Application | Drug Development, Drug Discovery, Other Applications |
| Delivery Type | Subscription Model, Ownership Model |
| End User | Biotechnology & Pharmaceutical Companies, Research Institutes, Regulatory Authorities, Contract Research Organizations |
| Country | United Kingdom, Germany, France, Italy |
Europe Biosimulation Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Dassault Systèmes
- Schrödinger
- Physiomics Plc
- Simulations Plus
- Insilico Biotechnology
- Genedata
- Argenx
- CureVac SE
- INOSIM Software GmbH
- Certara
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Application |
|
| Breakup by Delivery Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Europe Biosimulation Market Overview
3.1 Europe Biosimulation Market Historical Value (2017-2023)
3.2 Europe Biosimulation Market Forecast Value (2024-2032)
4 Europe Biosimulation Market Landscape*
4.1 Europe Biosimulation: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Europe Biosimulation: Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Application
5 Europe Biosimulation Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Europe Biosimulation Market Segmentation (2017-2032)
6.1 Europe Biosimulation Market (2017-2032) by Product Type
6.1.1 Market Overview
6.1.2 Software
6.1.3 Services
6.2 Europe Biosimulation Market (2017-2032) by Application
6.2.1 Market Overview
6.2.2 Drug Development
6.2.3 Drug Discovery
6.2.4 Other Applications
6.3 Europe Biosimulation Market (2017-2032) by Delivery Type
6.3.1 Market Overview
6.3.2 Subscription Model
6.3.3 Ownership Model
6.4 Europe Biosimulation Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Biotechnology & Pharmaceutical Companies
6.4.3 Research Institutes
6.4.4 Regulatory Authorities
6.4.5 Contract Research Organizations
6.5 Europe Biosimulation Market (2017-2032) by Country
6.5.1 Market Overview
6.5.2 United Kingdom
6.5.3 Germany
6.5.4 France
6.5.5 Italy
7 United Kingdom Biosimulation Market (2017-2032)
7.1 United Kingdom Biosimulation Market (2017-2032) by Product Type
7.1.1 Market Overview
7.1.2 Software
7.1.3 Services
7.2 United Kingdom Biosimulation Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Drug Development
7.2.3 Drug Discovery
7.2.4 Other Application
7.3 United Kingdom Biosimulation Market (2017-2032) by Delivery Type
7.3.1 Market Overview
7.3.2 Subscription Model
7.3.3 Ownership Model
7.4 United Kingdom Biosimulation Market (2017-2032) by End User
7.4.1 Market Overview
7.4.2 Biotechnology & Pharmaceutical Companies
7.4.3 Research Institutes
7.4.4 Regulatory Authorities
7.4.5 Contract Research Organizations
8 Germany Biosimulation Market (2017-2032)
8.1 Germany Biosimulation Market (2017-2032) by Product Type
8.1.1 Market Overview
8.1.2 Software
8.1.3 Services
8.2 Germany Biosimulation Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Drug Development
8.2.3 Drug Discovery
8.2.4 Other Application
8.3 Germany Biosimulation Market (2017-2032) by Delivery Type
8.3.1 Market Overview
8.3.2 Subscription Model
8.3.3 Ownership Model
8.4 Germany Biosimulation Market (2017-2032) by End User
8.4.1 Market Overview
8.4.2 Biotechnology & Pharmaceutical Companies
8.4.3 Research Institutes
8.4.4 Regulatory Authorities
8.4.5 Contract Research Organizations
9 France Biosimulation Market (2017-2032)
9.1 France Biosimulation Market (2017-2032) by Product Type
9.1.1 Market Overview
9.1.2 Software
9.1.3 Services
9.2 France Biosimulation Market (2017-2032) by Application
9.2.1 Market Overview
9.2.2 Drug Development
9.2.3 Drug Discovery
9.2.4 Other Application
9.3 France Biosimulation Market (2017-2032) by Delivery Type
9.3.1 Market Overview
9.3.2 Subscription Model
9.3.3 Ownership Model
9.4 France Biosimulation Market (2017-2032) by End User
9.4.1 Market Overview
9.4.2 Biotechnology & Pharmaceutical Companies
9.4.3 Research Institutes
9.4.4 Regulatory Authorities
9.4.5 Contract Research Organizations
10 Italy Biosimulation Market (2017-2032)
10.1 Italy Biosimulation Market (2017-2032) by Product Type
10.1.1 Market Overview
10.1.2 Software
10.1.3 Services
10.2 Italy Biosimulation Market (2017-2032) by Application
10.2.1 Market Overview
10.2.2 Drug Development
10.2.3 Drug Discovery
10.2.4 Other Application
10.3 Italy Biosimulation Market (2017-2032) by Delivery Type
10.3.1 Market Overview
10.3.2 Subscription Model
10.3.3 Ownership Model
10.4 Italy Biosimulation Market (2017-2032) by End User
10.4.1 Market Overview
10.4.2 Biotechnology & Pharmaceutical Companies
10.4.3 Research Institutes
10.4.4 Regulatory Authorities
10.4.5 Contract Research Organizations
11 Regulatory Framework
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication Year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by Year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by Departments
13.7 Analysis by Recipient Organization
14 Funding and Investment Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Supplier Landscape
16.1 Market Share by Top 5 Companies
16.2 Dassault Systèmes
16.2.1 Financial Analysis
16.2.2 Product Portfolio
16.2.3 Demographic Reach and Achievements
16.2.4 Mergers and Acquisitions
16.2.5 Certifications
16.3 Schrödinger
16.3.1 Financial Analysis
16.3.2 Product Portfolio
16.3.3 Demographic Reach and Achievements
16.3.4 Mergers and Acquisitions
16.3.5 Certifications
16.4 Physiomics Plc
16.4.1 Financial Analysis
16.4.2 Product Portfolio
16.4.3 Demographic Reach and Achievements
16.4.4 Mergers and Acquisitions
16.4.5 Certifications
16.5 Simulations Plus
16.5.1 Financial Analysis
16.5.2 Product Portfolio
16.5.3 Demographic Reach and Achievements
16.5.4 Mergers and Acquisitions
16.5.5 Certifications
16.6 Insilico Biotechnology
16.6.1 Financial Analysis
16.6.2 Product Portfolio
16.6.3 Demographic Reach and Achievements
16.6.4 Mergers and Acquisitions
16.6.5 Certifications
16.7 Genedata
16.7.1 Financial Analysis
16.7.2 Product Portfolio
16.7.3 Demographic Reach and Achievements
16.7.4 Mergers and Acquisitions
16.7.5 Certifications
16.8 Argenx
16.8.1 Financial Analysis
16.8.2 Product Portfolio
16.8.3 Demographic Reach and Achievements
16.8.4 Mergers and Acquisitions
16.8.5 Certifications
16.9 CureVac SE
16.9.1 Financial Analysis
16.9.2 Product Portfolio
16.9.3 Demographic Reach and Achievements
16.9.4 Mergers and Acquisitions
16.9.5 Certifications
16.10 INOSIM Software GmbH
16.10.1 Financial Analysis
16.10.2 Product Portfolio
16.10.3 Demographic
16.10.4 Mergers and Acquisitions
16.10.5 Certifications
16.11 Certara
16.11.1 Financial Analysis
16.11.2 Product Portfolio
16.11.3 Demographic Reach and Achievements
16.11.4 Mergers and Acquisitions
16.11.5 Certifications
17 Europe Biosimulation Market – Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The Europe biosimulation market is expected to be driven by the rising demand for the global biosimulation market, which is anticipated to grow at a CAGR of 16.90% during the forecast period of 2024-2032 and is likely to reach a market value of USD 14.1 billion by 2032.
The growing prevalence of chronic diseases and the rising healthcare expenditure are fuelling the demand for the market.
One of the significant trends in the market is the increased collaborative initiatives among the key market players to utilize biosimulation platforms in clinical applications. In March 2024, Exploristics and Exonate Ltd announced a successful collaboration involving optimizing the clinical trial design for Exonate’s upcoming Phase IIb study by leveraging a simulation-guided platform.
Based on the product type, the market is segmented into services and software.
By delivery type, the market is divided into the subscription model and ownership model.
End users of the market are biotechnology & pharmaceutical companies, research institutes, regulatory authorities, and contract research organizations.
Major applications of biosimulation include drug development and drug discovery, among others.
The market segmentation by countries includes the United Kingdom, Germany, France, and Italy.
The key players in the market are Dassault Systèmes, Schrödinger, Physiomics Plc, Simulations Plus, Insilico Biotechnology, Genedata, Argenx, CureVac SE, INOSIM Software GmbH, and Certara.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER